Unternavigation

COVID-19 Pandemic

Current status of authorisations for combating COVID-19

This table (“dashboard”) shows the applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.

Empfehlung des Bundesrates: Bleiben Sie zu Hause, insbesondere, wenn Sie alt oder krank sind

Information on the current situation in Switzerland

^{Information for health professionnals, FAQs, recommendations for travellers.}

Official information page

Covid-FAQ

FAQ on the COVID-19 vaccines

^{On this page you’ll find answers to frequently asked questions about mRNA vaccines.}

Product information

Comirnaty® 30 µg/dose for persons 12 years and older (purple cap) – Information for healthcare professionals (in German)

Comirnaty® 30 µg/dose for persons 12 years and older (purple cap) – Patient information (in German)

Comirnaty® 10 µg/dose for children 5 to <12 years (orange cap) – Information for healthcare professionals (in German)

Comirnaty® 10 µg/dose for children 5 to <12 years (orange cap) – Patient information (in German)

COVID-19 Vaccine Janssen - Information for healthcare professionals (in German)

COVID-19 Vaccine Janssen - Patient information (in German)

Spikevax – Information for healthcare professionals (in German)

Spikevax – Patient information (in German)

ZL000_00_044e_WL Guidance document Authorisation procedures for Covid-19 medicinal products during a pandemic (PDF, 218 kB, 01.08.2022)

Questions and answers on the packaging and labelling requirements for medicinal products intended to prevent or combat COVID-19

(status as of 16.09.2021)

FOPH - Coronavirus: häufig gestellte Fragen (FAQ)

(www.bag.admin.ch)

Vigilance-News Edition 28

All about the vaccines - briefly and concisely explained

Vaccines: Rapid solution for new diseases?

Swismedic - The way a vaccination works

How an mRNA vaccine works

How a vector vaccine works?

How a protein vaccine works

How is the safety of vaccines monitored?

Communication regarding COVID-19

Filter by theme

Results 1 - 10 of 100

22.09.2022

Pfizer AG applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

Application submitted for Comirnaty Original/Omicron BA.4-5

02.09.2022

COVID-19 vaccine Nuvaxovid: temporary authorisation from 12 years of age and as booster

Swissmedic authorises indication extension and booster

02.09.2022

Pfizer applies for indication extension of COVID-19 vaccine to include children aged 6 months to less than 5 years

Swissmedic reviews Pfizer Schweiz AG application for Comirnaty®

01.09.2022

Out-of-Stock – COVID-19 – Authorisations for the temporary import and distribution of human medicines – Update

Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3

29.08.2022

Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland

Moderna's Spikevax Bivalent Original/Omicron (mRNA-1273.214) authorised from age 18

26.08.2022

Reports of suspected adverse reactions to COVID-19 vaccines

15,781 reports of suspected adverse vaccination reactions evaluated

23.08.2022

Comirnaty® 30 micrograms/dose (PURPLE cap) – New shelf-life

Extended shelf live at ultra-low temperature

03.08.2022

Empfehlung bezüglich COVID-19 für die autologe Blutstammzellspende

Beschluss Vorschriften SBSC – Blutstammzellspende

02.08.2022

Pfizer applies for an authorisation extension for a coronavirus vaccine against Omicron

Comirnaty: Swissmedic starts rolling review of a bivalent COVID-19 vaccine

01.08.2022

Changes to Guidance document Authorisation procedures for COVID-19 medicinal products during a pandemic HMV4

Filing of Submission Plans to evaluate the efficacy of existing COVID-19 medicinal products against new SARS-Cov-2 variants

Results 1 - 10 of 100

https://www.swissmedic.ch/content/swissmedic/en/home/news/coronavirus-covid-19.html